JanisNaeve.jpg

At Amgen Ventures, we unlock value by making investments that match promising early innovations with more than 30 years of biotechnology experience.

Dr. Janis Naeve, Ph.D. serves as Managing Director and Managing Partner at Amgen Ventures. Ms. Naeve joined Amgen Ventures of DecImmune Therapeutics, Inc. in 2005 and directs its investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. She served as the Director of Corporate Development of X-Ceptor Therapeutics from 2002 to 2005.

Dr. Naeve served as a Director of Business Development at Aurora Biosciences, where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly, and Bristol Myers-Squibb. She serves as a Board Observer of VLST Corporation. She serves as a Director of Acylin Therapeutics, Inc. Dr. Naeve serves as a Director at Oncofactor Corporation, Groove Biopharma Corporation, and REN Pharmaceuticals, Inc.

She has been a Director at NexImmune, Inc. since July 17, 2014. Dr. Naeve served an Executive Director at the Amgen Ventures. She served as a Director at Amgen Ventures. She served as a Director of Accelerator Corporation. She has a Ph.D. in Pathology from University of Southern California and completed a Post-Doctoral Fellowship at the California Institute of Technology.

Fund's investment verticals: biotechnology companies focused on human therapeutics, oncology, inflammation, hematology, metabolic disorders and cardiovascular diseases.